OPTION-VMS (NCT06049797) is an ongoing Phase IV, longitudinal, observational, study of female participants aged 40-75 years with confirmed menopausal VMS who were prescribed a non-HT for the treatment ...
(RTTNews) - Astellas Pharma Inc. (ALPMY.PK), Wednesday announced new real-world preliminary data from the OPTION-VMS Phase IV study, a longitudinal, observational study in participants with VMS, also ...
The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has recommended grant of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback